A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Tolerability, Pharmacokinetic, Pharmacodynamic, and Preliminary Efficacy Trial of GTX-B001 in Healthy Volunteers (Part A) and Patients with Chronic Inducible Urticaria (Part B)

2025-522126-13-00 Protocol CHILL-MC Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 29 Aug 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 7 sites · Protocol CHILL-MC

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 56
Countries 1
Sites 7

Cold Induced Urticaria

Key facts

Sponsor
Granular Therapeutics Limited
Participant type
Patients, Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trial duration
29 Aug 2025 → ongoing
Decision date (initial)
2025-08-27
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Cold Induced Urticaria

VersionLevelCodeTermSystem organ class
21.1 LLT 10009870 Cold-induced urticaria 10040785

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Granular Therapeutics Limited

Sponsor organisation
Granular Therapeutics Limited
Address
Innovation House, Innovation Way, Discovery Park Innovation Way Discovery Park
City
Sandwich
Postcode
CT13 9FF
Country
United Kingdom

Scientific contact point

Organisation
Granular Therapeutics Limited
Contact name
Info-Granular

Public contact point

Organisation
Granular Therapeutics Limited
Contact name
Info-Granular

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 56 7
Rest of world 0

Investigational sites

Germany

7 sites · Ongoing, recruiting
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
Hautklinik und Poliklinik, Langenbeckstrasse 1, Oberstadt, Mainz
Universitatsklinikum Munster AöR
Department of Dermatology, Von-Esmarch-Strasse 58, Sentrup, Muenster
Dermatologische Praxis Dr. med. Abdou Zarzour
Hautarztpraxis Dr. med Abdou Zarour, Grosse Steinstrasse 12, 06108, Halle (Saale)
Universitaetsklinikum Giessen und Marburg GmbH
Klinik für Dermatologie und Allergologie, Baldingerstrasse 1, 35043, Marburg
Charite Research Organisation GmbH
Charite Research Organisation, Chariteplatz 1, Mitte, Berlin
Charite Universitaetsmedizin Berlin KöR
Institut für Allergieforschung IFA, Hindenburgdamm 30, Lichterfelde, Berlin
Universitaetsklinikum Tuebingen AöR
Studienzentrum Immundermatologie, Liebermeisterstrasse 25, Innenstadt, Tuebingen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-08-29 2025-09-15

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-06-06 Germany Acceptable
2025-08-26
2025-08-27
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-10-15 Germany Acceptable
2025-08-26
2025-10-15
3 SUBSTANTIAL MODIFICATION SM-1 2025-11-14 Germany Acceptable
2026-01-12
2026-01-16
4 SUBSTANTIAL MODIFICATION SM-2 2026-01-26 Germany Acceptable
2026-02-23
2026-02-27
5 NON SUBSTANTIAL MODIFICATION NSM-2 2026-03-17 Germany Acceptable
2026-02-23
2026-03-17
6 SUBSTANTIAL MODIFICATION SM-3 2026-04-09 Germany Acceptable 2026-05-29